XM无法为美国居民提供服务。
R
R

Roche

市场新闻

Assa Abloy, Kering, L'Oréal

EUROPE RESEARCH ROUNDUP-Assa Abloy, Kering, L'Oréal Oct 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Assa Abloy, Kering and L'Oréal, on Thursday. HIGHLIGHTS * Assa Abloy ASSAb.ST : Deutsche Bank raises target price to SEK 305 from SEK 300 * Barratt Redrow Plc BTRW.L : Morgan Stanley cuts target price to 580p from 600p * Dowlais Group Plc DWL.L : Citigroup raises to neutral from sell * Kering PRTP.PA : JP Morgan cuts target
B
D
D
D
E
E
H
H
K
K
L
L
P
R
R
R
S
S
S
S
S
T
Z
A
A
A
A
A
E
S

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R

Europe struggles for direction, earnings mixed

LIVE MARKETS-Europe struggles for direction, earnings mixed STOXX 600 flat Deutsche Bank, L'Oreal fall after earnings Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED European equities are mixed on Wednesday, after several corporate reports, with markets remaining on edge as the U.S.
D
I
L
L
R
S
V
S
E
F
U
G

Roche CEO comes out against approving takeover of drug manufacturer Catalent

Roche CEO comes out against approving takeover of drug manufacturer Catalent FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche ROG.S said competition authorities should not allow the controlling shareholder of Novo Nordisk NOVOb.CO to acquiring contract drug manufacturer Catalent CTLT.N . "It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available.
R

Europe before the bell: futures dip after raft of earnings

LIVE MARKETS-Europe before the bell: futures dip after raft of earnings Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS European stock futures are edging lower in early trade after a large number of corporate earnings, with markets also watching rising yields and preparing for the upcoming U.S.
D
I
L
P
R
V
E
F
U
G

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明